JP2022173349A5 - - Google Patents

Download PDF

Info

Publication number
JP2022173349A5
JP2022173349A5 JP2022152461A JP2022152461A JP2022173349A5 JP 2022173349 A5 JP2022173349 A5 JP 2022173349A5 JP 2022152461 A JP2022152461 A JP 2022152461A JP 2022152461 A JP2022152461 A JP 2022152461A JP 2022173349 A5 JP2022173349 A5 JP 2022173349A5
Authority
JP
Japan
Prior art keywords
integer
formula
independently
bond
inclusive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022152461A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022173349A (ja
JP7610559B2 (ja
Filing date
Publication date
Priority claimed from JP2019535879A external-priority patent/JP7167029B2/ja
Application filed filed Critical
Publication of JP2022173349A publication Critical patent/JP2022173349A/ja
Publication of JP2022173349A5 publication Critical patent/JP2022173349A5/ja
Priority to JP2024195755A priority Critical patent/JP2025016776A/ja
Application granted granted Critical
Publication of JP7610559B2 publication Critical patent/JP7610559B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022152461A 2016-12-30 2022-09-26 合成ガイド分子、それに関連する組成物および方法 Active JP7610559B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024195755A JP2025016776A (ja) 2016-12-30 2024-11-08 合成ガイド分子、それに関連する組成物および方法

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662441046P 2016-12-30 2016-12-30
US62/441,046 2016-12-30
US201762492001P 2017-04-28 2017-04-28
US62/492,001 2017-04-28
JP2019535879A JP7167029B2 (ja) 2016-12-30 2017-12-29 合成ガイド分子、それに関連する組成物および方法
PCT/US2017/069019 WO2018126176A1 (en) 2016-12-30 2017-12-29 Synthetic guide molecules, compositions and methods relating thereto

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019535879A Division JP7167029B2 (ja) 2016-12-30 2017-12-29 合成ガイド分子、それに関連する組成物および方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024195755A Division JP2025016776A (ja) 2016-12-30 2024-11-08 合成ガイド分子、それに関連する組成物および方法

Publications (3)

Publication Number Publication Date
JP2022173349A JP2022173349A (ja) 2022-11-18
JP2022173349A5 true JP2022173349A5 (https=) 2023-01-04
JP7610559B2 JP7610559B2 (ja) 2025-01-08

Family

ID=61187807

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019535879A Active JP7167029B2 (ja) 2016-12-30 2017-12-29 合成ガイド分子、それに関連する組成物および方法
JP2022152461A Active JP7610559B2 (ja) 2016-12-30 2022-09-26 合成ガイド分子、それに関連する組成物および方法
JP2024195755A Withdrawn JP2025016776A (ja) 2016-12-30 2024-11-08 合成ガイド分子、それに関連する組成物および方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019535879A Active JP7167029B2 (ja) 2016-12-30 2017-12-29 合成ガイド分子、それに関連する組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024195755A Withdrawn JP2025016776A (ja) 2016-12-30 2024-11-08 合成ガイド分子、それに関連する組成物および方法

Country Status (9)

Country Link
US (1) US20230111575A1 (https=)
EP (1) EP3565895A1 (https=)
JP (3) JP7167029B2 (https=)
KR (2) KR102758180B1 (https=)
CN (2) CN118345072A (https=)
AU (2) AU2017388753A1 (https=)
CA (1) CA3048434A1 (https=)
MX (1) MX420023B (https=)
WO (1) WO2018126176A1 (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015134812A1 (en) 2014-03-05 2015-09-11 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa
US11141493B2 (en) 2014-03-10 2021-10-12 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
US11339437B2 (en) 2014-03-10 2022-05-24 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
WO2015138510A1 (en) 2014-03-10 2015-09-17 Editas Medicine., Inc. Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10)
US11242525B2 (en) 2014-03-26 2022-02-08 Editas Medicine, Inc. CRISPR/CAS-related methods and compositions for treating sickle cell disease
US12460231B2 (en) 2014-04-02 2025-11-04 Editas Medicine, Inc. Crispr/CAS-related methods and compositions for treating primary open angle glaucoma
CA2982966C (en) 2015-04-24 2024-02-20 Editas Medicine, Inc. Evaluation of cas9 molecule/guide rna molecule complexes
WO2017165862A1 (en) 2016-03-25 2017-09-28 Editas Medicine, Inc. Systems and methods for treating alpha 1-antitrypsin (a1at) deficiency
EP3475424A1 (en) 2016-06-22 2019-05-01 ProQR Therapeutics II B.V. Single-stranded rna-editing oligonucleotides
WO2018026976A1 (en) 2016-08-02 2018-02-08 Editas Medicine, Inc. Compositions and methods for treating cep290 associated disease
US10941402B2 (en) 2016-09-01 2021-03-09 Proqr Therapeutics Ii B.V. Chemically modified single-stranded RNA-editing oligonucleotides
US11274300B2 (en) 2017-01-19 2022-03-15 Proqr Therapeutics Ii B.V. Oligonucleotide complexes for use in RNA editing
SG11201907870VA (en) 2017-02-28 2019-09-27 Vor Biopharma Inc Compositions and methods for inhibition of lineage specific proteins
EP3596217A1 (en) 2017-03-14 2020-01-22 Editas Medicine, Inc. Systems and methods for the treatment of hemoglobinopathies
US11499151B2 (en) 2017-04-28 2022-11-15 Editas Medicine, Inc. Methods and systems for analyzing guide RNA molecules
EP3622070A2 (en) 2017-05-10 2020-03-18 Editas Medicine, Inc. Crispr/rna-guided nuclease systems and methods
US11866726B2 (en) 2017-07-14 2024-01-09 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
US20190076814A1 (en) 2017-09-11 2019-03-14 Synthego Corporation Biopolymer synthesis system and method
WO2019178426A1 (en) 2018-03-14 2019-09-19 Editas Medicine, Inc. Systems and methods for the treatment of hemoglobinopathies
KR20210045360A (ko) 2018-05-16 2021-04-26 신테고 코포레이션 가이드 rna 설계 및 사용을 위한 방법 및 시스템
GB201808146D0 (en) 2018-05-18 2018-07-11 Proqr Therapeutics Ii Bv Stereospecific Linkages in RNA Editing Oligonucleotides
EP3823633A4 (en) 2018-06-29 2023-05-03 Editas Medicine, Inc. SYNTHETIC LEAD MOLECULES, COMPOSITIONS AND METHODS RELATED THERETO
CA3110837A1 (en) 2018-08-28 2020-03-05 Vor Biopharma Inc. Genetically engineered hematopoietic stem cells and uses thereof
GB201901873D0 (en) * 2019-02-11 2019-04-03 Proqr Therapeutics Ii Bv Antisense oligonucleotides for nucleic acid editing
CN114423865A (zh) 2019-05-23 2022-04-29 Vor生物制药股份有限公司 Cd33修饰的组合物和方法
AU2020336211A1 (en) 2019-08-28 2022-03-10 Vor Biopharma Inc. Compositions and methods for CD123 modification
US20220290160A1 (en) 2019-08-28 2022-09-15 Vor Biopharma Inc. Compositions and methods for cll1 modification
US20240110189A1 (en) 2020-08-28 2024-04-04 Vor Biopharma Inc. Compositions and methods for cll1 modification
US20240238344A1 (en) 2020-08-28 2024-07-18 Vor Biopharma Inc. Compositions and methods for cd123 modification
JP2023541457A (ja) 2020-09-14 2023-10-02 ブイオーアール バイオファーマ インコーポレーテッド Cd38修飾のための化合物および方法
WO2022056459A1 (en) 2020-09-14 2022-03-17 Vor Biopharma, Inc. Compositions and methods for cd5 modification
WO2022061115A1 (en) 2020-09-18 2022-03-24 Vor Biopharma Inc. Compositions and methods for cd7 modification
WO2022067240A1 (en) 2020-09-28 2022-03-31 Vor Biopharma, Inc. Compositions and methods for cd6 modification
US20230364146A1 (en) 2020-09-30 2023-11-16 Vor Biopharma Inc. Compositions and methods for cd30 gene modification
CA3199623A1 (en) 2020-10-27 2022-05-05 Vor Biopharma Inc. Compositions and methods for treating hematopoietic malignancy
WO2022094245A1 (en) 2020-10-30 2022-05-05 Vor Biopharma, Inc. Compositions and methods for bcma modification
JP2023550355A (ja) 2020-11-13 2023-12-01 ブイオーアール バイオファーマ インコーポレーテッド キメラ抗原受容体を発現する遺伝子操作された細胞に関連する方法および組成物
WO2022147347A1 (en) 2020-12-31 2022-07-07 Vor Biopharma Inc. Compositions and methods for cd34 gene modification
US20240200059A1 (en) 2021-04-09 2024-06-20 Vor Biopharma Inc. Photocleavable guide rnas and methods of use thereof
US20240384304A1 (en) 2021-07-06 2024-11-21 Vor Biopharma Inc. Inhibitor oligonucleotides and methods of use thereof
AU2022324093A1 (en) 2021-08-02 2024-02-08 Vor Biopharma Inc. Compositions and methods for gene modification
US20240417755A1 (en) 2021-09-27 2024-12-19 Vor Biopharma Inc. Fusion polypeptides for genetic editing and methods of use thereof
CA3236152A1 (en) 2021-11-09 2023-05-19 Vor Biopharma Inc. Compositions and methods for erm2 modification
US20250179531A1 (en) 2022-02-25 2025-06-05 Vor Biopharma Inc. Compositions and methods for homology-directed repair gene modification
US20250295695A1 (en) 2022-04-04 2025-09-25 Vor Biopharma Inc. Compositions and methods for mediating epitope engineering
WO2024015925A2 (en) 2022-07-13 2024-01-18 Vor Biopharma Inc. Compositions and methods for artificial protospacer adjacent motif (pam) generation
WO2024073751A1 (en) 2022-09-29 2024-04-04 Vor Biopharma Inc. Methods and compositions for gene modification and enrichment
EP4623081A2 (en) * 2022-11-23 2025-10-01 Prime Medicine, Inc. Split synthesis of long rnas
WO2024168312A1 (en) 2023-02-09 2024-08-15 Vor Biopharma Inc. Methods for treating hematopoietic malignancy
WO2025006216A2 (en) * 2023-06-29 2025-01-02 Synthego Corporation Methods and systems for automated fraction selection in nucleic acid manufacturing
WO2025030010A1 (en) 2023-08-01 2025-02-06 Vor Biopharma Inc. Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof
WO2025194138A1 (en) 2024-03-14 2025-09-18 Tessera Therapeutics, Inc. St1cas9 compositions and methods for modulating a genome

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX357240B (es) * 2011-10-10 2018-06-29 Kmt Waterjet Systems Inc Conexión de alta presion sin juntas.
AU2014346559B2 (en) * 2013-11-07 2020-07-09 Editas Medicine,Inc. CRISPR-related methods and compositions with governing gRNAs
WO2015138510A1 (en) 2014-03-10 2015-09-17 Editas Medicine., Inc. Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10)
US11242525B2 (en) * 2014-03-26 2022-02-08 Editas Medicine, Inc. CRISPR/CAS-related methods and compositions for treating sickle cell disease
WO2016057951A2 (en) * 2014-10-09 2016-04-14 Life Technologies Corporation Crispr oligonucleotides and gene editing
CA2963820A1 (en) 2014-11-07 2016-05-12 Editas Medicine, Inc. Methods for improving crispr/cas-mediated genome-editing
US10059940B2 (en) * 2015-01-27 2018-08-28 Minghong Zhong Chemically ligated RNAs for CRISPR/Cas9-lgRNA complexes as antiviral therapeutic agents
EP3280803B1 (en) * 2015-04-06 2021-05-26 The Board of Trustees of the Leland Stanford Junior University Chemically modified guide rnas for crispr/cas-mediated gene regulation
CA2982966C (en) * 2015-04-24 2024-02-20 Editas Medicine, Inc. Evaluation of cas9 molecule/guide rna molecule complexes
ES2835861T5 (en) * 2015-05-08 2025-02-18 Childrens Medical Ct Corp Targeting bcl11a enhancer functional regions for fetal hemoglobin reinduction
CN107709555A (zh) * 2015-05-15 2018-02-16 达尔马科恩有限公司 用于Cas9介导的基因编辑的合成的单向导RNA
US11518994B2 (en) * 2016-01-30 2022-12-06 Bonac Corporation Artificial single guide RNA and use thereof
EP3443088B1 (en) 2016-04-13 2024-09-18 Editas Medicine, Inc. Grna fusion molecules, gene editing systems, and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2022173349A5 (https=)
JP2020503049A5 (https=)
JP6839650B2 (ja) 核酸合成用修飾ヌクレオチド及び前記ヌクレオチドを含むキット、並びに合成核酸配列又は遺伝子の製造のためのそれらの使用
JP5548852B2 (ja) 疎水性基結合ヌクレオシド、疎水性基結合ヌクレオシド溶液、及び疎水性基結合オリゴヌクレオチド合成方法
AU2015350001B2 (en) Phosphoramidite synthones for the synthesis of self-neutralizing oligonucleotide compounds
EP0415901A2 (en) Improved nucleic acid probes
US20210283263A1 (en) Method of conjugating oligomeric compounds
AU769619B2 (en) Poly(ether-thioether), poly(ether-sulfoxide) and poly(ether-sulfone) nucleic acids
KR20190104392A (ko) 분자의 막투과 전달을 위한 화합물 및 방법
JPH09510206A (ja) オリゴヌクレオチドの合成に用いる組成物および方法
CA2436665A1 (en) Nucleic acid derivatives
JP2011184318A (ja) リボヌクレシドh−ボラノホスホネート
US5652350A (en) Complementary DNA and toxins
JPWO2019215333A5 (https=)
TW202112795A (zh) 使用經修改之氧化準則製備寡核苷酸之方法
US20180251485A1 (en) Pyrazolotriazolyl nucleoside analogues and oligonucleotides comprising them
CN101238213B (zh) 使用扭转嵌入核酸(TINA)稳定并选择性地形成Hoogsteen型三链体和双链体以及制备TINA的工艺
JPH06511236A (ja) シリルアルコールの合成方法
WO2017221929A1 (ja) リボ核酸h-ホスホネートモノマーの合成方法および本モノマーを用いたオリゴヌクレオチド合成
Lin et al. Hybridization properties of deoxyoligonucleotides containing anthraquinone pseudonucleosides
AU2018298658B2 (en) Improved process for preparing imetelstat
CN116333007B (zh) 一种基于点击化学的光响应性环形rna合成方法及其应用
WO2020158687A1 (ja) 光応答性ヌクレオチドアナログの製造方法
JP2020132604A (ja) 核酸合成用固相担体及びそれを用いた核酸の製造方法
JPWO2019175260A5 (https=)